303 The guanine analog triazavirin was reported to be a promising agent to treat SARS-CoV-2.304 A pilot trial by Wu et al. indicated that triazavirin can inhibit the tendency to bind to ACE2, and triazavirin showed a significantly better therapeutic effect and higher safety in the treatment of COVID-19 compared with a placebo or standard therapy.305. The gene discussed is ACE2; the disease is COVID-19.